skip to Main Content
About Us          Contact Us          |          
A lupus awareness and educational program from the American College of Rheumatology

All News

May is Lupus Awareness Month!

Did you know we offer complimentary teaching tools and resources to educators at medical and health profession schools? These resources are designed to help increase knowledge and awareness in the diagnosis and treatment of lupus and associated health disparities. Our robust collection includes educational slides, videos, and interactive and traditional case studies.  
Read More

MIMICT Advisory Committee Members in the News

ACR's Collaborative Initiatives department is proud to share the following interviews featuring members of our MIMICT Advisory Committee. Committee Member, Dr. Priscilla Pemu recently sat down with Atlanta's local NPR station, WABE,  to discuss "Reconciling Distrust in Clinical Research" in a special…

Read More

Expert Opinion: Learning from lupus

We all know that systemic lupus erythematosus disproportionately impacts women and racial and ethnic minorities. We also know that people of lower socioeconomic status are often diagnosed later and have poorer outcomes after diagnosis. The groups that are genetically at greater risk for SLE, namely women and minorities, are also more likely to be poor and uninsured.
Read More

A Functional Collaboration: The Lupus Initiative®

Over the past three years, members of The Lupus Initiative consortium have worked together to transform lupus education by leading an effort aimed at eliminating ethnic, racial, and gender disparities in the diagnosis and treatment of lupus through education. Because of these unique collaborations, this catalytic effort not only has the potential to produce meaningful outcomes; it has also established an effective model for success in educational philanthropy.
Read More

FDA Approves Benlysta to Treat Lupus Patients

Excerpted from FDA News Release, dated March 9, 2011 The US Food and Drug Administration (FDA) approved Benlysta (belimumab) for the treatment of lupus patients with active autoantibody- positive systemic lupus erythematosus (SLE).  The last drugs to receive FDA approval…

Read More
Back To Top